Events
-
-
-
ASCO 2026: Teclistamab extends survival, deepens remissions in relapsed multiple myeloma
-
ASCO 2026: Lancet Commission predict shortfall of 100 million cancer care workers by 2050
-
ASCO 2026: Phase 3 PEAK study could usher in new second-line therapy for GIST
-
ASCO 2026: Personalised vaccine boosts immune activity against brain cancer
-
ASCO 2026: GLP-1s may reduce metastatic progression of certain obesity-related cancers
-
ASCO 2026: Yoga may help cancer survivors sleep better and reduce anxiety, fatigue
-
-
AI may reshape cancer care from screening to drug discovery
Artificial intelligence (AI) is increasingly being applied across the cancer care pathway, from early detection…
“Electronic nose” may help identify ovarian cancer signatures from blood samples
A machine-learning–enabled “electronic nose” capable of identifying ovarian cancer–associated signatures from blood plasma samples has…
Tumour board–inspired AI system improves interpretation of oncology guidelines
A multi-agent artificial intelligence system designed to mimic the workflow of a multidisciplinary tumor board…
Hypertension treatment linked to lower mortality for patients with metastatic breast cancer
- The Lancet Oncology: Breast cancer remains the most common cancer among women worldwide, with annual cases expected to reach over 3.5 million by 2050
- Palbociclib improves progression-free survival in HR-positive, HER2-positive metastatic breast cancer
- Screening increases survival rate for stage IV breast cancer by 60%
Breaking Down Silos: How MPCCC is Transforming Cancer Care
Advancing Cancer Care For All | Rachael Babin discusses the ground-breaking work of the Monash Partners Comprehensive Cancer Consortium with Professor Mark Shackleton
Exosomal lnc-TAF12–2:1 identified as a novel diagnostic and therapeutic biomarker in bladder cancer
- TAR-200 monotherapy achieves high disease-free survival of more than 80 percent in BCG-unresponsive, high-risk papillary NMIBC
- TAR-200 monotherapy demonstrates highest complete response rate reported to date with sustained clinical benefits in patients with certain types of bladder cancer
- Enfortumab vedotin plus pembrolizumab in advanced bladder cancer: Hint of major added benefit
Building the AI-enabled medical school of the future: A new era in clinician education?
In a viewpoint letter published in JAMA on 31 March 2025, Marc D. Succi, Bernard S. Chang and Arya S.…
JOIN THE ONCOLOGY NETWORK
If you would like even more free news articles, access to our exclusive HCP only content including the latest podcasts from The Oncology Podcast and our Industry Partner Podcasts (including links to all papers and show notes), along with all our other resources, head over to The Oncology Network and sign up - FREE forever for HCPs only.